Skip to main content
Premium Trial:

Request an Annual Quote

Genetix, Sense Proteomic to Collaborate on Protein Arrays

NEW YORK, Oct. 31 - Genetix Group of New Milton, UK, said Wednesday it had agreed to collaborate with Sense Proteomic to develop a new line of protein arrays.

Genetix said it agreed to work with Sense Proteomic’s of Cambridge, UK, to deploy Sense’s COVET technology in four prototype products. The companies expect to launch the new arrays commercially next year. 

According to Genetix, the COVET technology can express, purify, and array thousands of proteins in a spatially defined format. The proteins arrayed are correctly folded and fully functional, allowing users to more easily identify new drug targets and potential candidates.

“The Genetix Group, like others in the industry, view protein arrays as an area of growth,” Mark Reid, CEO of Genetix, said in a statement. “Sense Proteomic has a unique technology and product portfolio and it is an exciting challenge to help bring these products to market.”

The companies did not disclose the financial terms of the deal.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.